Galectin-3 as immunological target
AssigneeThe Johns Hopkins University
InventorsElizabeth Marion Jaffee, Lanqing Huang, Lei Zheng
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe Johns Hopkins University
InventorsElizabeth Marion Jaffee, Lanqing Huang, Lei Zheng
Estimating the term…
AnnexinA2 (ANXA2), a member of the Annexin family of calcium-dependent, phospholipid binding proteins, is one of a panel of identified antigens recognized by the post-vaccination sera of patients who demonstrated prolonged disease-free survival following multiple vaccinations. AnnexinA2 is abundantly expressed in pancreatic adenocarcinomas and cell surface/membrane AnnexinA2 increases with the progression from premalignant lesions to invasive pancreatic adenocarcinomas. The cytoplasmic to cell surface translocation of AnnexinA2 expression is critical for pancreatic cancer cell invasion. In addition, phosphorylation of AnnexinA2 at Tyrosine 23 is important for its localization to the cell surface and for the invasion of pancreatic cancer cells. Finally, loss of AnnexinA2 leads to the loss of the Epithelial-Mesenchymal Transition.
-17. (canceled)
A method of inhibiting a tumor in a patient comprising
A method of inhibiting tumor metastasis comprising
A method of determining a favorable clinical outcome in a pancreatic ductal adenocarcinoma patient whose tumor has been resected, wherein the patient has received a GM-CSF-secreting pancreatic tumor vaccine comprising:
Dependencies are inferred from the claim text.